Nickel Marius K, Loew Thomas H, Pedrosa Gil Francisco
Clinic for Psychosomatic Medicine and Psychotherapy, Medical University of Graz, 8990, Bad Aussee, Austria.
Psychopharmacology (Berl). 2007 May;191(4):1023-6. doi: 10.1007/s00213-007-0740-0. Epub 2007 Feb 23.
Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state-trait anger expression inventory (STAXI). OBJECTIVES, MATERIALS, AND METHODS: To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomatology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).
According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.
Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.
已知仅有一项对照试验对边缘型人格障碍（BPD）患者使用了阿立哌唑。这项为期8周的试验发现，症状清单（SCL - 90 - R）、汉密尔顿抑郁评定量表（HDRS）、汉密尔顿焦虑评定量表（HARS）的大多数量表以及状态 - 特质愤怒表达量表（STAXI）的所有量表均有显著变化。目的、材料与方法：为评估阿立哌唑对多方面边缘型症状的长期疗效，对先前试验中的同一批患者进行了为期18个月的随访观察，每半年进行一次测试（先前每日服用15毫克阿立哌唑治疗组，n = 26，21名女性和5名男性患者；先前安慰剂组，n = 26，22名女性和4名男性患者）。
根据意向性分析原则，18个月后，在接受阿立哌唑治疗的受试者中，观察到SCL - 90 - R、HDRS、HARS和STAXI的所有量表均有显著变化。
阿立哌唑在长期治疗BPD患者方面似乎是一种有效且相对安全的药物。
